Skip to content
Acute Kidney Injury

Acute Kidney Injury

Quick read: Stage the AKI, rule out urgent complications (hyperkalemia, acidosis, pulmonary oedema, obstruction, RPGN/TMA), classify as pre-renal / intrinsic / post-renal, then treat the cause.
🚨 Do not miss
Anuria (consider obstruction or cortical necrosis) · RPGN (active sediment + rapid decline, biopsy urgently) · Severe hyperkalaemia (K⁺ >6.5 or ECG changes) · Uraemic pericarditis or encephalopathy · TMA (microangiopathic haemolytic anaemia + thrombocytopenia)
💡 Clinical pearl
FENa <1% suggests pre-renal physiology but is unreliable after diuretics, contrast, myoglobinuria or early obstruction. Use FEUrea <35% instead in these settings.
Practical orientation: Use this page as a triage tool. Identify urgent complications first, then work through the differential systematically.
Use first: clinical summary and algorithm.
Then: differential diagnosis, workup and management tables.
Escalate: use red flags and biopsy / RRT sections.

Clinical summary

Definition
Sudden loss of kidney function — rising creatinine and/or reduced urine output over hours to days.
First step
Stage severity, establish baseline, assess volume status, drugs, sepsis and obstruction.
Do not miss
Anuria, RPGN, TMA, obstruction, severe hyperkalaemia, acidosis, pulmonary oedema, uraemia.
Core tests
BMP, Ca, PO4, albumin, CPK, UA with microscopy, UPCR/UACR, CBC — plus imaging when needed.
Treatment
Supportive care plus cause-specific treatment; RRT for refractory complications.

Algorithm

AKI clinical algorithm

Staging

Stage Creatinine criterion Urine output criterion
1 Rise ≥0.3 mg/dL within 48 h, or 1.5–1.99× baseline within 7 days <0.5 mL/kg/h for 6–12 h
2 2.0–2.99× baseline <0.5 mL/kg/h for ≥12 h
3 ≥3× baseline, creatinine ≥4.0 mg/dL, or need for RRT <0.3 mL/kg/h for ≥24 h or anuria ≥12 h

Causes

Category Important causes
Pre-renal Hypovolaemia, cirrhosis, shock, cardiorenal physiology, abdominal compartment syndrome, hepatorenal syndrome, hypercalcaemia
Intrinsic — glomerular GN, RPGN, anti-GBM disease, immune-complex GN, ANCA vasculitis
Intrinsic — vascular/TMA TTP/HUS, DIC, complement-mediated or drug-mediated TMA, APS, malignant HTN, scleroderma renal crisis, renal artery/vein occlusion
Intrinsic — tubular ATN from sepsis/ischaemia/toxins, cast nephropathy, crystal nephropathy
Intrinsic — interstitial Drug-induced AIN, infection, SLE, Sjögren, IgG4 disease, sarcoidosis, TINU
Post-renal Stones, BPH/prostate cancer, malignancy, clots, papillary necrosis

Urine findings

Finding Consider
Bland sediment or hyaline casts Pre-renal AKI or obstruction
Muddy-brown granular casts / RTE cells ATN
Dysmorphic RBCs or RBC casts GN or vasculitis
WBC casts AIN, pyelonephritis or GN
Crystals Drug crystals, uric acid, calcium oxalate, phosphate nephropathy

Pre-renal vs ATN pattern

Measurement Pre-renal ATN
BUN/Cr ratio >20:1 <20:1
Specific gravity >1.020 ~1.010
Urine osmolality >500 mOsm/kg <350 mOsm/kg
Urine sodium <10–20 mmol/L >20–40 mmol/L
FENa <1% >2%
FEUrea <35% >35%

Indications for kidney biopsy in AKI

  • Unresolving AKI without clear diagnosis after 2–3 weeks
  • Suspected GN or RPGN
  • Suspected AIN when steroid therapy is under consideration
  • Suspected paraprotein-related kidney disease
  • Active sediment or nephrotic-range proteinuria with unclear aetiology

Prevention

Measure Practical approach
Nephrotoxins Minimise contrast, NSAIDs, aminoglycosides and other toxic drug exposures
Haemodynamics Avoid volume depletion and hypotension, especially perioperatively
Dosing Adjust all medications to current kidney function
Fluids Prefer crystalloids; balanced crystalloids (Hartmann’s / PlasmaLyte) often reasonable
Contrast Use minimal volume of low/iso-osmolar contrast; isotonic fluid pre-/post-procedure if tolerated

Management

Step Action
Cause Treat sepsis, hypovolaemia, obstruction, RPGN, TMA or toxin exposure
Complications Treat hyperkalaemia, acidosis, pulmonary oedema and uraemia promptly
Medications Stop nephrotoxins; dose-adjust renally cleared drugs
Diuretics Use for volume control only — they do not accelerate renal recovery
RRT Start for refractory acidosis, hyperkalaemia, volume overload, uraemic complications or dialysable toxin

RRT

Indications, timing and modality selection

Absolute indications (start without delay):

  • Refractory hyperkalaemia (K⁺ >6.5 mmol/L or ECG changes)
  • Refractory metabolic acidosis (pH <7.1 or bicarbonate <12)
  • Refractory pulmonary oedema
  • Uraemic pericarditis, encephalopathy or bleeding
  • Dialysable toxin (lithium, methanol, ethylene glycol, salicylates)

Relative/anticipated indications:

  • Oliguria or anuria with progressive fluid accumulation
  • Creatinine rising without clinical recovery after adequate treatment
  • AKI stage 3 with multi-organ failure

Modality choice:

  • CRRT preferred in haemodynamically unstable patients (ICU)
  • Intermittent HD in stable patients with adequate haemodynamics
  • SLED/hybrid as intermediate option
  • Peritoneal dialysis in selected settings (paediatric, resource-limited)

Timing: Current evidence (AKIKI, IDEAL-ICU, STARRT-AKI trials) does not support routine early initiation. Start based on clinical indications rather than creatinine thresholds alone.

Prognosis

Recovery depends on injury severity and duration, baseline kidney function and comorbidity burden. Nonoliguric ATN generally carries a better prognosis than oliguric ATN.

Long-term outcomes and follow-up
  • Full recovery from ATN typically takes 6–12 weeks; monitor closely during this period
  • AKI increases long-term risk of CKD, ESRD, cardiovascular events and mortality
  • Hospital-acquired AKI should trigger nephrology follow-up at 3 months even if creatinine normalises
  • Any patient with AKI stage 2–3 or AKI on background CKD warrants nephrology review
  • Check urine albumin/protein at 3-month follow-up — persistent proteinuria after AKI suggests underlying glomerular disease or developing CKD